HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tumour morphology after neoadjuvant chemotherapy as a predictor of survival in serous ovarian cancer: an experience from a tertiary care centre in India.

Abstract
Serous ovarian cancer is the most common malignant ovarian tumour. Traditional management consists of surgical resection with postoperative chemotherapy. Currently neoadjuvant chemotherapy is offered to patients with advanced stage disease. The present study aims to analyse the histomorphological alterations in serous ovarian cancer following neoadjuvant chemotherapy. Correlation of these morphological alterations with survival is also presented here. Serous ovarian cancers from 100 advanced stage cases were included; 50 were treated with pre-surgery chemotherapy. Semi-quantitative scoring was used to grade the alterations in tumour morphology. Survival data was correlated with the final morphological score. Tumour morphology was significantly different in cases treated with neoadjuvant chemotherapy (CT group) as compared to cases with upfront surgery. The CT group cases showed more fibrosis, calcification, and infiltration by lymphocytes, plasma cells, foamy and hemosiderin-laden macrophages. The residual tumour cells had degenerative cytoplasmic changes with nuclear atypia. Patients with significant morphological response had a longer median survival, although it did not attain statistical significance in the current study. With the increasing use of neoadjuvant chemotherapy in management, the pathologist needs to be aware of the altered morphological appearance of tumour. Further studies are required to establish a grading system to assess the tissue response which can be helpful in predicting the overall therapeutic outcome and the prognosis of patients.
AuthorsBinny Khandakar, Lalit Kumar, Sunesh Kumar, Siddharth Datta Gupta, M Kalaivani, Venkateswaran K Iyer, Sandeep R Mathur
JournalThe Malaysian journal of pathology (Malays J Pathol) Vol. 37 Issue 2 Pg. 115-21 (Aug 2015) ISSN: 0126-8635 [Print] Malaysia
PMID26277668 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Topics
  • Adult
  • Aged
  • Chemotherapy, Adjuvant (methods)
  • Cystadenocarcinoma, Serous (drug therapy, mortality, pathology)
  • Female
  • Humans
  • India
  • Kaplan-Meier Estimate
  • Middle Aged
  • Neoadjuvant Therapy (methods)
  • Ovarian Neoplasms (drug therapy, mortality, pathology)
  • Prospective Studies
  • Retrospective Studies
  • Tertiary Care Centers

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: